|
EP3574094A4
(en)
|
2017-01-24 |
2020-11-11 |
Northwestern University |
LOW MOLECULAR WEIGHT ACTIVE VARIANTS OF ANGIOTENSIN II CONVERTING ENZYME (ECA II)
|
|
CA3082610A1
(en)
|
2017-11-29 |
2019-06-06 |
Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
|
|
JP7340372B2
(ja)
*
|
2019-07-11 |
2023-09-07 |
浜松ホトニクス株式会社 |
光活性化アデニル酸シクラーゼ
|
|
CA3165586A1
(en)
*
|
2020-01-23 |
2021-07-29 |
Avirus, Inc. |
Methods and compositions for treating and preventing viral infection
|
|
US11518788B2
(en)
*
|
2020-07-10 |
2022-12-06 |
Avirus, Inc. |
Methods and compositions for treating and preventing viral infection
|
|
US20210236583A1
(en)
*
|
2020-02-03 |
2021-08-05 |
Yuntao Wu |
Targeting the renin-angiotensin system for treatment of environment-and pathogen-induced lung injury
|
|
US20230250410A1
(en)
*
|
2020-02-13 |
2023-08-10 |
Systimmune, Inc. |
Recombinant ace2-fc fusion molecules and methods of making and using thereof
|
|
TWI886211B
(zh)
*
|
2020-02-13 |
2025-06-11 |
美商西雅圖免疫公司 |
重組ace2-fc融合分子以及製造及使用彼等之方法
|
|
EP3893890B1
(en)
*
|
2020-02-20 |
2025-12-10 |
Sheau-Long Lee |
Ginsenoside m1 for use in the treatment of damages in organs or tissues in a subject caused by infection with coronavirus
|
|
CN111474363A
(zh)
*
|
2020-02-22 |
2020-07-31 |
安徽华培生物科技有限公司 |
一种新型冠状病毒检测方法
|
|
WO2021174107A2
(en)
*
|
2020-02-26 |
2021-09-02 |
Northwestern University |
Soluble ace2 variants and uses therefor
|
|
KR20220147121A
(ko)
*
|
2020-02-27 |
2022-11-02 |
화후이 헬스 리미티드 |
가용성 ace2 및 융합 단백질, 및 이의 응용
|
|
WO2021170113A1
(zh)
*
|
2020-02-29 |
2021-09-02 |
南京金斯瑞生物科技有限公司 |
ACE-2-Fc融合蛋白治疗冠状病毒的方法
|
|
EP4118109A1
(en)
|
2020-03-11 |
2023-01-18 |
NantCell, Inc. |
Proteinaceous therapeutics
|
|
US20210284716A1
(en)
|
2020-03-11 |
2021-09-16 |
Immunitybio, Inc. |
ACE2-Fc Trap
|
|
US11857620B2
(en)
|
2020-03-11 |
2024-01-02 |
Immunitybio, Inc. |
Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
|
|
US12285480B2
(en)
|
2020-03-11 |
2025-04-29 |
Nantcell, Inc. |
Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
|
|
EP3946612A4
(en)
*
|
2020-03-21 |
2024-11-20 |
Larix Biosciences LLC |
BISPECIFIC AND TRISPECIFIC FUNCTIONAL MOLECULES OF ACE2 AND COMPLEMENT PATHWAYS AND THEIR USE
|
|
WO2021195009A1
(en)
*
|
2020-03-23 |
2021-09-30 |
Sapience Therapeutics, Inc. |
Peptide antagonists of ace2-binding proteins
|
|
CN113444710A
(zh)
*
|
2020-03-25 |
2021-09-28 |
上海英脉德医疗科技有限公司 |
ACE2-Fc融合蛋白及其用途
|
|
WO2021202456A1
(en)
*
|
2020-03-30 |
2021-10-07 |
The Wistar Institute Of Anatomy And Biology |
Synthetic soluble receptor mimics and methods of use for treatment of covid-19
|
|
WO2021197501A1
(zh)
*
|
2020-04-02 |
2021-10-07 |
创观（苏州）生物科技有限公司 |
病毒不易感动物
|
|
AU2021248665A1
(en)
*
|
2020-04-03 |
2022-11-10 |
The University Of North Carolina At Chapel Hill |
Binding proteins useful against ACE2-targeted viruses
|
|
US20230203466A1
(en)
*
|
2020-04-03 |
2023-06-29 |
Medgenome Inc. |
Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
|
|
WO2021216547A1
(en)
*
|
2020-04-20 |
2021-10-28 |
Sorrento Therapeutics, Inc. |
Pulmonary administration of ace2 polypeptides
|
|
US20210386837A1
(en)
*
|
2020-05-18 |
2021-12-16 |
Northwestern University |
Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
|
|
US11773385B2
(en)
*
|
2020-05-19 |
2023-10-03 |
Children's Medical Center Corporation |
High-affinity human ACE2 construct for use in diagnosing and treating coronaviruses
|
|
WO2021247675A1
(en)
*
|
2020-06-02 |
2021-12-09 |
Ngm Biopharmaceuticals, Inc. |
Coronavirus-binding agents and uses thereof
|
|
DE102020207224A1
(de)
|
2020-06-09 |
2021-12-09 |
Christoph Karle |
Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon
|
|
US20230242672A1
(en)
*
|
2020-06-25 |
2023-08-03 |
Gliknik Inc. |
Ace2-fc fusion proteins and methods of use
|
|
WO2022008642A1
(en)
|
2020-07-08 |
2022-01-13 |
Apeiron Biologics Ag |
Treatment of sars-cov-2 infection with a combination of targets
|
|
WO2022012688A1
(en)
*
|
2020-07-17 |
2022-01-20 |
Shenzhen Bay Laboratory |
Ace2-ig fusion variants
|
|
KR102492081B1
(ko)
*
|
2020-07-28 |
2023-01-26 |
재단법인대구경북과학기술원 |
코로나바이러스 감염증 covid-19 치료용 펩타이드 및 이의 용도
|
|
EP4192859A1
(en)
*
|
2020-08-06 |
2023-06-14 |
BioNTech SE |
Binding agents for coronavirus s protein
|
|
US20220041660A1
(en)
*
|
2020-08-06 |
2022-02-10 |
University Of Delaware |
Compositions and methods for sequestering viral particles in respiratory tract
|
|
WO2022035998A1
(en)
*
|
2020-08-11 |
2022-02-17 |
City Of Hope |
Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
|
|
WO2022072757A1
(en)
*
|
2020-10-01 |
2022-04-07 |
Systimmune, Inc. |
Recombinant ace2-fc fusion molecules and methods of making and using thereof
|
|
WO2022075667A1
(ko)
*
|
2020-10-05 |
2022-04-14 |
한양대학교 산학협력단 |
안정화된 ace2 변이체, 이를 이용한 ace2-fc 융합단백질 및 covid-19 예방 또는 치료용 약학 조성물
|
|
AU2021362007A1
(en)
*
|
2020-10-16 |
2023-06-22 |
Invisishield Technologies Ltd. |
Compositions for preventing or treating viral and other microbial infections
|
|
EP4249499A4
(en)
*
|
2020-11-20 |
2025-01-01 |
Daegu Gyeongbuk Institute Of Science and Technology |
Coronavirus infectious disease covid-19 therapeutic proteins ctp alpha, ctp beta, ctp gamma, ctp delta, and uses thereof
|
|
BR112023009875A2
(pt)
|
2020-11-23 |
2024-02-06 |
Genentech Inc |
Métodos para tratar um indivíduo com uma infecção por sars-cov-2, para reduzir a ligação de sars-cov-2 a uma célula, para diminuir a infecção por sars-cov-2 e para identificar um modulador, métodos de profilaxia, moduladores isolados, usos e antagonistas
|
|
WO2022119380A1
(ko)
*
|
2020-12-03 |
2022-06-09 |
주식회사 유틸렉스 |
신규한 ace2 변이체 및 그의 이용
|
|
EP4011387A1
(en)
*
|
2020-12-11 |
2022-06-15 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2
|
|
US20220226489A1
(en)
|
2021-01-20 |
2022-07-21 |
Singh Biotechnology, Llc |
Therapeutics directed against coronavirus
|
|
JP2024505203A
(ja)
*
|
2021-01-26 |
2024-02-05 |
ナショナル リサーチ カウンシル オブ カナダ |
Ａｃｅ２受容体エクトドメイン融合分子及びその使用
|
|
WO2022165246A1
(en)
*
|
2021-01-29 |
2022-08-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and method of use of mutant ace2 decoy variants
|
|
JP7539479B2
(ja)
*
|
2021-02-10 |
2024-08-23 |
シーチュアン バイリ ファーマスーティカル シーオー． エルティーディー． |
組換えａｃｅ２－ｆｃ融合分子、その製造方法及びその使用
|
|
WO2022207918A1
(en)
|
2021-04-02 |
2022-10-06 |
Apeiron Biologics Ag |
COVID-19 Therapy
|
|
US20240360181A1
(en)
*
|
2021-05-20 |
2024-10-31 |
Achelois Biopharma, Inc. |
Compositions and methods for multivalent surface display on enveloped particles
|
|
CN113324933B
(zh)
*
|
2021-06-01 |
2022-07-26 |
浙江大学 |
一种检测血管紧张素转换酶的方法及其应用
|
|
US20240270797A1
(en)
*
|
2021-06-23 |
2024-08-15 |
Cz Biohub Sf, Llc |
Coronavirus neutralizing compositions and associated methods
|
|
EP4444344A2
(en)
*
|
2021-12-09 |
2024-10-16 |
Gliknik Inc. |
Ace2-fc fusion proteins and methods of use
|
|
WO2023201306A1
(en)
|
2022-04-14 |
2023-10-19 |
Invisishield Technologies Ltd. |
Compositions for preventing or treating influenza infections
|
|
JP2025512512A
(ja)
|
2022-04-14 |
2025-04-17 |
インビジシールド テクノロジーズ リミテッド |
コロナウイルス感染症の予防又は治療のための組成物
|
|
EP4335870A1
(en)
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptide therapeutics against sars-cov-2 spike protein
|
|
CN116023509A
(zh)
*
|
2022-11-18 |
2023-04-28 |
中国药科大学 |
一种融合蛋白及其应用
|
|
DE202023100085U1
(de)
|
2023-01-09 |
2023-02-03 |
Sundararajan Gothandam |
Eine doppelte Blockade des Renin-Angiotensin-Systems zur Verringerung der frühen Veränderungen der diabetischen Retinopathie und Nephropathie
|
|
CN118085110A
(zh)
*
|
2024-04-02 |
2024-05-28 |
中国药科大学 |
一种靶向肿瘤的融合蛋白及其应用
|